Circulating Levels of Phosphorylated Tau Protein Differentiate Alzheimer’s Disease from other Types of Dementia

A blood-based test for AD would be a less invasive and less expensive screening tool than the currently approved cerebrospinal fluid or amyloid-beta positron emission tomography (PET) diagnostic tests.

In an effort to develop a blood-based test for AD, investigators at the University of California, San Francisco (USA) examined whether plasma tau protein phosphorylated at residue 181 (pTau181) could differentiate between clinically diagnosed or autopsy-confirmed AD and frontotemporal lobar degeneration.

Subjects aged from 58 to 70 years were tested to measure plasma pTau181. Participants in the study included 56 who had been diagnosed with AD, 47 with mild cognitive impairment, and 69 healthy controls. In addition, the study group included 190 individuals with different types of frontotemporal dementia, a group of brain disorders caused by degeneration of the frontal and temporal lobes, areas of the brain associated with decision-making, behavioral control, emotion, and language.

Among healthy controls pTau181 averaged 2.4 picograms per milliliter, among those with mild cognitive impairment 3.7 picograms per milliliter, and for those with AD 8.4 picograms per milliliter. In people with variants of frontotemporal dementia, levels ranged from 1.9 to 2.8 picograms per milliliter. Thus, the results revealed that plasma pTau181 concentrations were increased by 3.5-fold in AD compared to controls and differentiated AD from both clinically diagnosed and autopsy-confirmed frontotemporal lobar degeneration.

"This test could eventually be deployed in a primary care setting for people with memory concerns to identify who should be referred to specialized centers to participate in clinical trials or to be treated with new Alzheimer's therapies, once they are approved," said senior author Dr. Adam Boxer, professor of neurology at the University of California, San Francisco. "Being able to easily diagnose Alzheimer's disease at early stages may be especially beneficial to patients with mild cognitive impairment, some of whom may have early Alzheimer's disease. Individuals with early Alzheimer's are more likely to respond to many of the new treatments that are being developed."

The phosphorylated tau study was published in the March 2, 2020, online edition of the journal Nature Medicine.

Related Links:
University of California, San Francisco